You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級丨美銀:上調信達生物目標價至61.1港元 上調今明兩年銷售預測
格隆匯 04-25 15:05

美銀證券發表報告表示,信達生物今年2月旗下達伯舒及達攸同銷售分別按年升47.6%及32.3%至1.79億及1.14億元,達伯華銷售按年升15.4%至5150萬元。同時,睿妥及Tafolecimab銷售分別按年升53.2%及2.13倍。該行基於主要產品強勁銷售,上調今明兩年銷售預測1%。

該行又指,公司宣佈將在2025年ASCO年會進行七場報告,其中三場關於達伯舒的新進展。該行把信達生物目標價從52港元上調至61.1港元,重申“買入”評級,基於強勁銷售表現和穩健的產品線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account